

Daily Activity

Table of Contents		
(Dates and starting pages for yearly citations and selected events)		
Date	Event	Page
10-01-2004	Begin Cited Diligence Activity for Year 2004	
10-26-2004	2-Year Rat Carcinogenicity Study (Study No. P00012-04-11) – dosing begins	
11-24-2004	C-1900 Phase IIb Human Study – dosing begins	
01-01-2005	Begin Cited Diligence Activity for Year 2005	
06-28-2005	2-Year Mouse Carcinogenicity Study (Study No. P00012-05-03) – dosing begins	
10-18-2005	11-Month Dog Toxicity Study (Study No. P00012-05-05) – dosing begins	
01-01-2006	Begin Cited Diligence Activity for Year 2006	1
01-17-2006	1-Year Monkey Toxicity Study (Study No. P00012-05-08) – dosing begins	
02-22-2006	Biogen files IND 73,061 (BG-12 MS treatment)	
03-01-2006	C-1900 Phase IIb Human Study – dosing ends	
08-30-2006	End of Phase II meeting for IND 73,061 (BG-12 MS treatment)	50
09-13-2006	11-Month Dog Toxicity Study (Study No. P00012-05-05) – dosing ends	56
10-26-2006	2-Year Rat Carcinogenicity Study (Study No. P00012-04-11) – dosing ends	73
01-01-2007	Begin Cited Diligence Activity for Year 2007	95
01-02-2007	Phase III Human Study – patient/study site recruiting begins	95
01-15-2007	1-Year Monkey Toxicity Study (Study No. P00012-05-08) – dosing ends	100
02-08-2007	Constructive RTP – US Prov. App. No. 60/888,921 filed	108
03-14-2007	109-MS-301 Phase III Human Study – dosing begins	
06-25-2007	2-Year Mouse Carcinogenicity Study (Study No. P00012-05-03) – dosing ends	
07-28-2007	109-MS-302 Phase III Human Study – dosing begins	

Key of Letter Symbols for Study Activities
the following abbreviations are used throughout the daily diligence chart

DA	<p><u>Dosing Animals</u> From at least as early as Sept. 2004 until June 2007, Biogen conducted five overlapping, nonclinical (animal) studies as part of its BG-12 program. Completion of these nonclinical (animal) studies necessitated a variety of activities, including the daily administration of a composition containing DMF to study animals, which is designated in the chart below with the abbreviation “DA.”</p>
R/E	<p><u>Recruiting and Enrolling Patients and Sites</u> Successful initiation and completion of Biogen’s Phase IIb clinical trial and subsequent Phase III clinical trials required significant recruitment and enrollment of MS patients and trial study sites to carry out Biogen’s clinical trial protocols. These recruitment and enrollment efforts are designated in the chart below with the abbreviation “R/E.”</p>
CD Ph3	<p><u>Clinical Development toward Phase III</u> Once the Phase IIb clinical trial was underway, Biogen worked continuously on numerous tasks required to further advance its clinical development of BG-12 toward Phase III, such as preparing and filing IND 73,061 (BG-12 MS treatment), preparing Phase III designs and protocols, corresponding with the FDA and other regulatory agencies, and performing Phase III start-up activities. These activities to further advance clinical development toward Phase III clinical trials are collectively designated below with the abbreviation “CD Ph3.”</p>

Summary of Nonclinical Study Dosing Dates

Biogen conducted certain nonclinical (animal) studies in developing BG-12, each study involving a range of daily dosing dates. The daily diligence chart below uses color-coded columns to show those date ranges during which study subjects received a study dose within a respective trial. This condensed representation of those dosing date ranges illustrates the overlapping nature of these studies.

	2004	2005	2006	2007	2008	2009	2010	2011
<u>P00012-04-11:</u> <u>2-Year Rat Carcinogenicity Study</u> <ul style="list-style-type: none"> • Ex. 2375 at 18; Ex. 2274 at 1, 10, 20. 		10/26/04 to 10/23/06						
<u>P00012-05-03</u> <u>2-Year Mouse Carcinogenicity Study</u> <ul style="list-style-type: none"> • Ex. 2375 at 26; Ex. 2377 at 1, 10, 18-19. 			6/28/05 to 6/25/07					
<u>P00012-05-05</u> <u>11-Month Dog Repeat Dose Toxicity Study</u> <ul style="list-style-type: none"> • Ex. 2085 at 77; Ex. 2275 at 1, 9, 14-16. 			10/18/05 to 9/13/06					
<u>P00012-05-08</u> <u>1-Year Monkey Repeat Dose Toxicity Study</u> <ul style="list-style-type: none"> • Ex. 2085 at 68; Ex. 2276 at 1, 9-11. 			1/17/06 to 1/15/07					

Daily Diligence Chart

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/1/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/2/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/3/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/4/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/5/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/6/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/7/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/8/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/9/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/10/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/11/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/12/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/13/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/14/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/15/2006 (Mon)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/16/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/17/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/18/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/19/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/20/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/21/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/22/2006 (Mon)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/23/2006 (Tues)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/24/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/25/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/26/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4	Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/27/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
05/28/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
05/29/2006 (Mon)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 52, 53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/30/2006 (Tues)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
05/31/2006 (Wed)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-16:8; 17:1-8; 17:16-18:18; 22:2-4</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 49-53 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2343; Ex. 2350 at 1; Ex. 2122 at 2; Ex. 2252 at 1; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2079 ¶¶ 40-43 (Ex. 2255; Ex. 2252 at 1; Ex. 2122 at 2; Ex. 2131 at 1; Ex. 2115 at 1; Ex. 2124 at 2);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/1/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/2/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/3/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/4/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/5/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26,45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/6/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/7/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/8/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/9/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/10/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/11/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/12/2006 (Mon)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/13/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/14/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/15/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/16/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/17/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11)</p>	DA	DA	DA	DA
06/18/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/19/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/20/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/21/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/22/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/23/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35, 55 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2332)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/24/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11) ;</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/25/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 57, 58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/26/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/27/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/28/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
06/29/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
06/30/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:8-14; 17:8-13; 18:15-19:17; 22:4-7	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 54-58 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2345 at 1; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2; Ex. 2352; Ex. 2321 at 1, 2; Ex. 2351 at 1, 2; Ex. 2346; Ex. 2341; Ex. 2105; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 9, 15-25, 33, 34 (Ex. 2316 at 5; Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2128 at 1; Ex. 2352);</p> <p>Ex. 2079 ¶¶ 44-47 (Ex. 2277; Ex. 2105; Ex. 2116; Ex. 2125; Ex. 2126 at 3; Ex. 2316 at 1, 2, 6; Ex. 2279 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/1/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/2/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/3/2006 (Mon)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2079 ¶¶ 48-51 (Ex. 2316 at 1-3, 5; Ex. 2127 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/4/2006 (Tues)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/5/2006 (Wed)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2079 ¶¶ 48-51 (Ex. 2316 at 1-3, 5; Ex. 2127 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/6/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
07/7/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/8/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26,, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/9/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/10/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/11/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19- 20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
07/12/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19- 20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/13/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/14/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/15/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/16/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/17/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/18/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
07/19/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/20/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/21/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/22/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/23/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/24/2006 (Mon)	DA CD Ph3	<p>DA: 13:17-15:6</p> <p>CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13</p>	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/25/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19- 20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
07/26/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19- 20:7; 22:7-13	Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19); Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/27/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/28/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35, 60-61 (Ex. 2274; Ex. 2330 at 6-9, 21, 28, 34, 35, 37; Ex. 2281; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2327; Ex. 2296)</p>	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
07/29/2006 (Sat)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/30/2006 (Sun)	DA	DA: 13:17-15:6	<p>Ex. 2076 ¶¶ 25, 26, 45, 61, 62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA
07/31/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-14; 18:19-20:7; 22:7-13	<p>Ex. 2076 ¶¶ 25, 26, 45, 47, 59-62 (Ex. 2262 at 1; Ex. 2375; Ex. 2275 at 9, 14-16; Ex. 2276 at 9-11; Ex. 2381; Ex. 2364; Ex. 2316; Ex. 2365; Ex. 2366; Ex. 2274 at 20, 21; Ex. 2377 at 19);</p> <p>Ex. 2077 ¶¶ 15-25, 33, 35-41 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 3-6; Ex. 2132; Ex. 2316 at 1, 2, 5, 6; Ex. 2344 at 1-5; Ex. 2134 at 1; Ex. 2106 at 1-3; Ex. 2339 at 7; Ex. 2308 at 1; Ex. 2327 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA	DA	DA

DA = dosing animals

CD Ph3 = Phase III clinical development

R/E = recruiting/enrolling sites/patients

*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/1/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/2/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/3/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/4/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/5/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/6/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/7/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/8/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/9/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/10/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/11/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/12/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/13/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/14/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/15/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/16/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/17/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/18/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/19/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/20/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/21/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/22/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/23/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/24/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/25/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/26/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/27/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/28/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/29/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
08/30/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶¶ 7, 25 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11; Ex. 2297 at 1, 2); Ex. 2080 ¶¶ 25-35, 66 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2297)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
08/31/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 20:8-21:4; 22:10-13	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-25, 33, 42-46 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2297 at 2-6; Ex. 2361 at 1; Ex. 2235; Ex. 2239; Ex. 2237; Ex. 2240); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/1/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/2/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/3/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/4/2006 (Mon)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/5/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/6/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/7/2006 (Thur)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/8/2006 (Fri)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/9/2006 (Sat)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/10/2006 (Sun)	DA	DA: 13:17-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/11/2006 (Mon)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11) Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA
09/12/2006 (Tues)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA	DA	DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/13/2006 (Wed)	DA CD Ph3	DA: 13:17-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 77-95, 128-179; Ex. 2275 at 9, 14-16; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2275 at 9, 14, 15; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-35, 65 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2275; Ex. 2285; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2328)	DA	DA	DA	DA
09/14/2006 (Thur)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11) Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/15/2006 (Fri)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/16/2006 (Sat)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/17/2006 (Sun)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/18/2006 (Mon)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/19/2006 (Tues)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/20/2006 (Wed)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/21/2006 (Thur)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/22/2006 (Fri)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/23/2006 (Sat)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/24/2006 (Sun)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/25/2006 (Mon)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/26/2006 (Tues)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/27/2006 (Wed)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/28/2006 (Thur)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
09/29/2006 (Fri)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:12-16; 21:5-13; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 47-52 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2228 at 1; Ex. 2234 at 1, 2, 4; Ex. 2229 at 1; Ex. 2241 at 2, 3, 6; Ex. 2236; Ex. 2242 at 2, 3; Ex. 2238; Ex. 2225 at 1; Ex. 2328 at 1; Ex. 2226 at 1; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
09/30/2006 (Sat)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/1/2006 (Sun)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/2/2006 (Mon)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/3/2006 (Tues)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/4/2006 (Wed)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35, 66 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2297)	DA	DA		DA
10/5/2006 (Thur)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11) Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/6/2006 (Fri)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35, 67 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/7/2006 (Sat)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/8/2006 (Sun)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/9/2006 (Mon)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/10/2006 (Tues)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/11/2006 (Wed)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/12/2006 (Thur)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/13/2006 (Fri)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/14/2006 (Sat)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/15/2006 (Sun)	DA	DA: 13:17-14:13; 14:19-15:6	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA		DA
10/16/2006 (Mon)	DA CD Ph3	<p>DA: 13:17-14:13; 14:19-15:6</p> <p>CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5</p>	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA		DA
10/17/2006 (Tues)	DA CD Ph3	<p>DA: 13:17-14:13; 14:19-15:6</p> <p>CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5</p>	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/18/2006 (Wed)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/19/2006 (Thur)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/20/2006 (Fri)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/21/2006 (Sat)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/22/2006 (Sun)	DA	DA: 13:17-14:13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/23/2006 (Mon)	DA CD Ph3	DA: 13:17-14:13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17-20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 128-179; Ex. 2375 at 18, 26; Ex. 2377 at 10, 18, 19; Ex. 2274 at 10, 20, 21; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 18, 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 25-29, 33-35 (Ex. 2274; Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2283; Ex. 2375 at 18, 25, 26; Ex. 2085 at 68-74, 128-52; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)	DA	DA		DA
10/24/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1 Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
10/25/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/26/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
10/27/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35, 68 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2227; Ex. 2086)		DA		DA
10/28/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
10/29/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
10/30/2006 (Mon)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
10/31/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:13-17; 22:14-23:5	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 53-56 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2233; Ex. 2232; Ex. 2231 at 1; Ex. 2230 at 1; Ex. 2227 at 1; Ex. 2086; Ex. 2090 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/1/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/2/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35, 69 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2299; Ex. 2087; Ex. 2294 at 2)		DA		DA
11/3/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35, 69 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2299; Ex. 2087; Ex. 2294 at 2)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/4/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/5/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/6/2006 (Mon)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/7/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/8/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/9/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)			
			2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/10/2006 (Fri)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6		DA		DA
11/11/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6		DA		DA
11/12/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/13/2006 (Mon)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/14/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/15/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/16/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/17/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/18/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/19/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>		DA		DA
11/20/2006 (Mon)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>		DA		DA
11/21/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/22/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/23/2006 (Thur)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/24/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/25/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>		DA		DA
11/26/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>		DA		DA
11/27/2006 (Mon)	DA CD Ph3	<p>DA: 13:17-14:2; 14:9-13; 14:19-15:6</p> <p>CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14</p>	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
11/28/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/29/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
11/30/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 16:14-16; 21:17-20; 23:6-14	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 57-61 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2215 at 3, 9; Ex. 2214 at 2-5; Ex. 2206 at 2, 4, 5; Ex. 2216 at 3, 4, 6; Ex. 2090 at 1; Ex. 2222 at 1; Ex. 2210 at 1-3; Ex. 2219 at 1); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/1/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/2/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/3/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/4/2006 (Mon)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/5/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/6/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/7/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/8/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/9/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/10/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/11/2006 (Mon)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35, 70 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286; Ex. 2294; Ex. 2333)		DA		DA
12/12/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/13/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/14/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/15/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/16/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/17/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/18/2006 (Mon)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/19/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/20/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/21/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/22/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/23/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/24/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/25/2006 (Mon)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/26/2006 (Tues)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/27/2006 (Wed)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/28/2006 (Thur)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/29/2006 (Fri)	DA CD Ph3	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 23:15-24:1	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 62-65 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2217 at 2, 3; Ex. 2218 at 1, 2; Ex. 2211 at 2); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
12/30/2006 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
12/31/2006 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/1/2007 (Mon)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/2/2007 (Tues)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/3/2007 (Wed)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/4/2007 (Thur)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/5/2007 (Fri)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/6/2007 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/7/2007 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/8/2007 (Mon)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence							
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)							
			2Y Rat	2Y Mouse	11M Dog	1Y Monk.				
01/9/2007 (Tues)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>					DA		DA
01/10/2007 (Wed)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>					DA		DA
01/11/2007 (Thur)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>					DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/12/2007 (Fri)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 14:19-15:6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/13/2007 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA
01/14/2007 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11); Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10); Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11) Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)		DA		DA

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/15/2007 (Mon)	DA	DA: 13:17-14:2; 14:9-13; 14:19-15:6	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2077 ¶¶ 15, 17, 19, 20 (Ex. 2087 at 1; Ex. 2085 at 68-74, 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2276 at 1, 9, 10);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26; Ex. 2276 at 9-11);</p> <p>Ex. 2080 ¶¶ 27-29, 33-35 (Ex. 2330 at 6-8, 28, 35, 37; Ex. 2281 at 34, 37-39, 50-54; Ex. 2375 at 25, 26; Ex. 2085 at 68-74; Ex. 2377; Ex. 2284; Ex. 2226; Ex. 2326; Ex. 2276; Ex. 2286)</p>		DA		DA
01/16/2007 (Tues)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26);</p> <p>Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26);</p> <p>Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)</p>		DA		
01/17/2007 (Wed)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	<p>Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26);</p> <p>Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3);</p> <p>Ex. 2078 ¶ 7 (Ex. 2375 at 26);</p> <p>Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)</p>		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/18/2007 (Thur)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/19/2007 (Fri)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/20/2007 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 15:4-6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/21/2007 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 15:4-6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/22/2007 (Mon)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/23/2007 (Tues)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/24/2007 (Wed)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/25/2007 (Thur)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/26/2007 (Fri)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/27/2007 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 15:4-6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/28/2007 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 15:4-6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/29/2007 (Mon)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
01/30/2007 (Tues)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
01/31/2007 (Wed)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:2-7	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 66-69 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2219 at 1; Ex. 2196 at 2, 3; Ex. 2220 at 1, 2; Ex. 2213 at 1, 2; Ex. 2221 at 2, 3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
02/1/2007 (Thur)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:8-25:10	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 70-74 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2212 at 2, 3; Ex. 2198 at 1-3; Ex. 2203 at 1-3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
02/2/2007 (Fri)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:8-25:10	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 70-74 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2212 at 2, 3; Ex. 2198 at 1-3; Ex. 2203 at 1-3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
02/3/2007 (Sat)	DA	DA: 13:17-14:2; 14:9-13; 15:4-6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
02/4/2007 (Sun)	DA	DA: 13:17-14:2; 14:9-13; 15:4-6	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
02/5/2007 (Mon)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:8-25:10	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 70-74 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2212 at 2, 3; Ex. 2198 at 1-3; Ex. 2203 at 1-3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
02/6/2007 (Tues)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:8-25:10	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 70-74 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2212 at 2, 3; Ex. 2198 at 1-3; Ex. 2203 at 1-3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
02/7/2007 (Wed)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:8-25:10	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 70-74 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2212 at 2, 3; Ex. 2198 at 1-3; Ex. 2203 at 1-3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays

Date (Day)	All Activity	Motion Citations (page:line)	All Supporting Evidence	Daily Dosing			
			Exhibit Citations for All Activities Declaration Ex. (Exhibits cited therein)	2Y Rat	2Y Mouse	11M Dog	1Y Monk.
02/8/2007 (Thur)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:8-25:10	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 70-74 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2212 at 2, 3; Ex. 2198 at 1-3; Ex. 2203 at 1-3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		
02/9/2007 (Fri)	DA CD Ph3 R/E	DA: 13:17-14:2; 14:9-13; 15:4-6 CD Ph3: 15:9-12; 21:17-20; 24:8-25:10	Ex. 2076 ¶¶ 25, 26 (Ex. 2262 at 1; Ex. 2375 at 26); Ex. 2077 ¶¶ 15, 17, 20, 26-33, 70-74 (Ex. 2087 at 1; Ex. 2085 at 153-179; Ex. 2375 at 26; Ex. 2377 at 10, 18, 19; Ex. 2245 at 2, 13; Ex. 2244 at 2, 15; Ex. 2082 at 5, 7; Ex. 2083 at 5-7; Ex. 2212 at 2, 3; Ex. 2198 at 1-3; Ex. 2203 at 1-3); Ex. 2078 ¶ 7 (Ex. 2375 at 26); Ex. 2080 ¶¶ 27-29 (Ex. 2377; Ex. 2330 at 28, 37; Ex. 2281 at 34, 50-52; Ex. 2284; Ex. 2375 at 26; Ex. 2226)		DA		

DA = dosing animals
R/E = recruiting/enrolling sites/patients

CD Ph3 = Phase III clinical development
*Gray rows = weekends and/or holidays